Nutriband Inc.
NTRBNutriband Inc. in brief
Nutriband Inc. is a listed company in the Biotechnology industry, based in Orlando, Florida, USA. Its market value was $79 M on 29 October 2026, which makes it the 19,642nd largest listed company in the world and the 3,645th largest in the USA on this site. In the year to January 2026 it had sales of $2 M and a net loss of $8 M. Its largest product and service lines by sales in 2026 were Sale of Goods (100%). By market, the largest shares of its 2026 sales came from USA (100%). Its shares trade under the symbol NTRB (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Nutriband Inc.
Nutriband Inc., was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary AVERSA™ abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs.
The Company’s revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics. Pocono Pharmaceuticals provides contract manufacturing services for health, wellness and over-the-counter pharmaceutical customers and 4P Therapeutics performs contract research and development related services for pharmaceutical and medical devices customers. We manage and evaluate our operations, and report our financial results, through these two separate subsidiaries.
From the company's annual report filed with the US SEC: read the report
Nutriband Inc. timeline
- 2016
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2024
- 💰Record revenue of $2 millionFY2024, the highest of the 8 years on record.
Events of Nutriband Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,877 (Jan 2020) · #3,735 (Jan 2021) · #4,930 (Jan 2022) · #5,112 (Dec 2022) · #4,958 (Jul 2023) · #4,375 (Jan 2024) · #2,124 (Mar 2026) · #3,800 (Aug 2026) · #3,620 (Oct 2026) · #3,649 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 48.7×
- Price / book
- 11.8×
- Free cash flow yield
- -6.5%
- Net margin (TTM)
- -429.6%
- Operating margin
- -407.8%
- Return on equity
- -104.2%
- Liabilities / assets
- 11.5%
- Revenue growth
- -4.7%
- R&D / revenue
- 92.6%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jan 2026 | $2M | -4.7% | $-8M | $-8M | -403.4% |
| Jan 2025 | $2M | +2.4% | $-10M | $-10M | -489.7% |
| Jan 2024 | $2M | +0.5% | $-5M | $-5M | -262.7% |
| Jan 2023 | $2M | +46.5% | $-4M | $-4M | -215.4% |
| Jan 2022 | $1M | +51.1% | $-6M | $-6M | -435.2% |
| Jan 2021 | $1M | +154.1% | $-3M | $-3M | -311.7% |
| Jan 2020 | $0M | +48.0% | $-2M | $-3M | -735.1% |
| Jan 2019 | $0M | — | $-3M | $-3M | -1332.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jan 2026 | $-5M | $0M | $-5M | $-2.58 | — |
| Jan 2025 | $-5M | $0M | $-5M | $-0.99 | — |
| Jan 2024 | $-4M | $0M | $-4M | $-0.69 | — |
| Jan 2023 | $-3M | $0M | $-3M | $-0.53 | — |
| Jan 2022 | $-3M | $0M | $-3M | $-0.80 | — |
| Jan 2021 | $-0M | — | — | $-0.51 | — |
| Jan 2020 | $-1M | — | — | $-0.50 | — |
| Jan 2019 | $-1M | $0M | $-1M | $-0.62 | — |
Quarterly results
Latest quarter to Jul 2026: revenue $0M (-29.0% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jul 2026.
SEC filings
- Sep 23, 20268-KCurrent reportRegulation FD disclosure
- Sep 4, 202610-QQuarterly report · period to Jul 2026
- Jun 22, 20268-KCurrent reportMaterial agreement
- Jun 11, 202610-QQuarterly report · period to Apr 2026
- May 18, 202610-K/AAnnual report (amended) · period to Jan 2026
- Apr 29, 202610-KAnnual report · period to Jan 2026
- Apr 7, 20268-KCurrent reportRegulation FD disclosure
- Feb 13, 20268-KCurrent reportRegulation FD disclosure
- Feb 3, 20268-KCurrent reportShareholder vote
- Dec 30, 20258-KCurrent reportRegulation FD disclosure
- Dec 19, 2025DEF 14AProxy statement
- Dec 11, 202510-QQuarterly report · period to Oct 2025
Official filings of Nutriband Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $2 M
- Operating income
- $-8 M
- Net income
- $-8 M
For year ending January-2026 · source: SEC filing
Balance sheet
- Total assets
- $8 M
- Total liabilities
- $1 M
- Total equity
- $7 M
As of January-2026
Top 19 institutional investors in Nutriband Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 174,927 | 0 (0.00%) | 1.44% | $1 M | Nov 13, 2026 |
| 2 | Geode Capital Management, LLC | 66,045 | +3,551 (+5.68%) | 0.54% | $0 M | Nov 6, 2026 |
| 3 | Vanguard Fiduciary Trust Co | 32,331 | +7,220 (+28.75%) | 0.27% | $0 M | Nov 13, 2026 |
| 4 | State Street Corp | 24,966 | 0 (0.00%) | 0.21% | $0 M | Nov 12, 2026 |
| 5 | BFC Planning, Inc. | 18,000 | -1,000 (-5.26%) | 0.15% | $0 M | Nov 13, 2026 |
| 6 | UBS Group AG | 17,057 | +16,385 (+2438.24%) | 0.14% | $0 M | Nov 10, 2026 |
| 7 | Cetera Investment Advisers | 15,989 | New | 0.13% | $0 M | Nov 13, 2026 |
| 8 | BlackRock, Inc. | 12,129 | +1,467 (+13.76%) | 0.10% | $0 M | Nov 13, 2026 |
| 9 | Northern Trust Corp | 11,570 | 0 (0.00%) | 0.10% | $0 M | Nov 16, 2026 |
| 10 | Haven Private, LLC | 11,317 | -49 (-0.43%) | 0.09% | $0 M | Oct 27, 2026 |
| 11 | Tower Research Capital LLC (TRC) | 3,991 | +1,884 (+89.42%) | 0.03% | $0 M | Nov 16, 2026 |
| 12 | Osaic Holdings, Inc. | 3,100 | -584 (-15.85%) | 0.03% | $0 M | Nov 12, 2026 |
| 13 | Vanguard Global Advisers, LLC | 2,700 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 14 | Wells Fargo & Company/mn | 2,600 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 15 | Jones Financial Companies Lllp | 466 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 16 | Citigroup Inc | 231 | New | 0.00% | $0 M | Nov 4, 2026 |
| 17 | Farther Finance Advisors, LLC | 90 | New | 0.00% | $0 M | Oct 8, 2026 |
| 18 | Harbour Investments, Inc. | 3 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 19 | Caitong International Asset Management Co., Ltd | 2 | New | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Nutriband Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 122,586 | $0 M | 1.0% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 52,341 | $0 M | 0.43% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 32,875 | $0 M | 0.27% | <0.01% | +38% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 9,774 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 9,994 | $0 M | 0.08% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 8,237 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 7,231 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 668 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 8 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Nutriband Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Gerald GoodmanChief Financial Officer | Exercise of in-the-money derivative | +60,085 | $1.930 | $116 K | 66,085 | Form 5 |
| filed | Serguei MelnikChairman and President, Director, 10% owner | Gift | -5,000 | — | — | 827,999 | Form 4 |
| filed | Gareth SheridanCEO, Director, 10% owner | Gift | -10,000 | — | — | 1.51 M | Form 4 |
| filed | Gareth SheridanCEO, Director, 10% owner | Grant or award | +10,000 | $3.800 | $38 K | 1.52 M | Form 4 |
| filed | Serguei MelnikChairman and President, Director | Buyamended | +500 | $4.030 | $2 K | 633,000 | Form 4/A |
| filed | Serguei MelnikChairman and President, Director | Buyamended | -500 | $4.030 | $2 K | 633,000 | Form 4/A |
| filed | Serguei MelnikChairman and President, Director | Buy | -5,000 | $4.030 | $20 K | 637,500 | Form 4 |
| filed | Serguei MelnikChairman and President, Director | Gift | -10,000 | — | — | 632,500 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Nutriband Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-04-30 13:34 UTC, code LUDP, resumed 13:39 UTC
- 2025-01-22 15:13 UTC, code LUDP, resumed 15:18 UTC
Fails to deliver
- : 689 shares at $6.49
- : 305 shares at $5.95
- : 750 shares at $5.97
- : 3,418 shares at $6.00
- : 2,693 shares at $6.27
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Nutriband Inc. scorecard#
Passes 3 of the 21 checks that could be worked out: strongest in financial health (2 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median11.8×Price to book 11.8× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median48.7×Price to sales 48.7× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-6.5%Free cash flow is -6.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✗Revenue grew in the newest year-4.7%Revenue down 4.7% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-0.7%-0.7% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-0.7%-0.7% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-2.58 vs -0.99Diluted EPS -2.58 in fiscal 2025 against -0.99 the year before (report's currency).
- ✗Net income higher than five years earlier-$8 M-$8 M in fiscal 2025 against -$3 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-407.8%-407.8% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-125.5%-125.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-407.8%-407.8% in fiscal 2025 against -215.4% in 2022.
Financial health2 of 4
- ✓Short-term assets cover short-term liabilities6.4×Current ratio 6.40 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-416.0×Operating income -416.0 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone43.05Z-score 43.05 (safe zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year9.8%Diluted shares up 9.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Nutriband Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -407.8% | -60.5% | |
| Net margin | -403.4% | -68.9% | |
| Return on equity | -125.6% | -61.0% | |
| Revenue growth, 3 years a year | -0.7% | 12.9% | |
| Revenue growth | -4.7% | 15.8% | |
| Free cash flow margin | -252.0% | -61.5% |
3of 8on the Piotroski tests of financial strength
- Revenue fell 4.7% against the year before.
- Net loss of $8 million, the 10th loss-making year in a row.
- Free cash flow was negative: -$5 million.
- The share count rose 9.8% in the year.
Nutriband Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Jan 31, 2026 | FY 2024to Jan 31, 2025 | FY 2023to Jan 31, 2024 | FY 2022to Jan 31, 2023 | FY 2021to Jan 31, 2022 | FY 2020to Jan 31, 2021 | FY 2019to Jan 31, 2020 | FY 2018to Jan 31, 2019 | FY 2017to Jan 31, 2018 | FY 2016to Jan 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 2,037−4.8%100% | 2,140+2.6%100% | 2,085+0.3%100% | 2,080+46.2%100% | 1,422+50.7%100% | 944+155%100% | 371+51.1%100% | 245—100% | — | — | |
| Cost of revenue | 1,470+5.3%72.2% | 1,396+14.1%65.3% | 1,223−8.0%58.7% | 1,329+44.8%63.9% | 918+46.3%64.5% | 627r582+14.3%66.5% | 549+90.5%148% | 288—118% | — | — | |
| Gross profit | 566−23.8%27.8% | 743−13.8%34.7% | 862+14.9%41.3% | 750+35.4%36.1% | 554+75.3%39.0% | 316—33.5% | — | — | — | — | |
| Research and development | 1,891−39.4%92.9% | 3,119+59.1%146% | 1,960+99.6%94.0% | 982+139%47.2% | 411—28.9% | — | — | — | — | — | |
| Selling, general and administrative | 6,993+62.1%343% | 4,314+14.3%202% | 3,774−3.6%181% | 3,916−2.7%188% | 4,023+38.1%283% | 2,912r2,957+62.6%309% | 1,791−45.5%483% | 3,288+1812%1341% | 172+13.7%— | 151—— | |
| Operating expenses | 8,884−19.4%436% | 11,028+92.3%515% | 5,734—275% | — | 6,615+127%465% | 2,912+24.5%309% | 2,340−34.6%631% | 3,577+33.9%1458% | 2,672—— | — | |
| Total costs and expenses | 10,355−16.7%508% | 12,424+78.6%581% | 6,957+6.1%334% | 6,555−13.0%315% | 7,533+113%530% | 3,540+51.3%375% | 2,340—631% | — | 2,672+1666%— | 151—— | |
| Operating income | −8,318—−408% | −10,285—−481% | −4,872—−234% | −4,475—−215% | −6,111—−430% | −2,596—−275% | −1,969—−531% | −3,331—−1358% | −2,672—— | −151—— | |
| Interest and finance income | 111−42.2%5.4% | 192+1038%9.0% | 17—0.8% | — | — | — | — | — | — | — | |
| Interest expense and finance costs | 23+5.3%1.1% | 21−71.8%1.0% | 76+815%3.6% | 8.3−93.0%0.4% | 118−57.8%8.3% | 281r8.6+282%29.7% | 73—19.8% | — | — | — | |
| Other non-operating income (expense) | 88—4.3% | −198—−9.2% | −613−112%−29.4% | 5,226−21.0%251% | 6,615r−65—465% | −337—−35.7% | −752—−203% | — | — | — | |
| Income before tax | −8,230—−404% | −10,483—−490% | −5,485—−263% | −4,483—−216% | −6,176—−434% | −2,933—−311% | −2,722—−734% | −3,331—−1358% | −2,672—— | — | |
| Income from continuing operations | −1,728—−84.9% | −2,201r2,201−291%−103% | 1,152r−1,152—55.2% | −942r942−173%−45.3% | 1,297—91.2% | — | — | — | — | — | |
| Net income including minority interests | — | — | — | — | −6,176—−434% | −2,933—−311% | −2,767r−2,722—−746% | −3,331—−1358% | −2,672—— | −151—— | |
| Net income attributable to shareholders | −8,230—−404% | −10,483—−490% | −5,485—−263% | −4,483—−216% | −6,176—−434% | −2,933—−311% | −2,722—−734% | −3,331—−1358% | −2,672—— | −151—— | |
| Earnings per share, basic | -2.58—— | -0.99—— | -0.69—— | -0.53—— | -0.80r-0.94—— | -0.51—— | -0.50—— | -0.62r-0.16—— | -0.14—— | -0.01—— | |
| Earnings per share, diluted | -2.58—— | -0.99—— | -0.69—— | -0.53—— | -0.80—— | -0.51—— | -0.50—— | -0.62r-0.16—— | -0.14—— | -0.01—— | |
| Shares, weighted average (basic) | 12+9.7%— | 11+33.4%— | 8.0−6.0%— | 8.5+6.6%— | 7.9—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 12+9.7%— | 11+33.4%— | 8.0−6.0%— | 8.5+6.6%— | 7.9r6.8+37.5%— | 5.8+6.4%— | 5.4+1.3%— | 5.4r21−72.1%— | 19−9.4%— | 21—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 4,575+6.1%60.6% | 4,312+775%57.7% | 493−75.2%6.6% | 1,985−59.4%21.0% | 4,892+3118%38.4% | 152+1393%1.5% | 10−97.9%0.5% | 475—16.9% | — | 27—71.9% | |
| Receivables | 118+60.3%1.6% | 74−50.3%1.0% | 149+31.5%2.0% | 113+58.4%1.2% | 71−34.7%0.6% | 109+752%1.1% | 13−1.9%0.6% | 13—0.5% | — | — | |
| Inventory | 118−44.4%1.6% | 212+25.8%2.8% | 169−26.5%2.2% | 229+74.2%2.4% | 132+149%1.0% | 53—0.5% | — | — | 4.1−48.6%2.5% | 8.0—21.3% | |
| Current assets | 4,989+4.1%66.1% | 4,794+369%64.2% | 1,022−62.1%13.6% | 2,694−50.7%28.5% | 5,465+1640%42.9% | 314+628%3.2% | 43−92.7%2.0% | 590+258%21.0% | 165+337%100% | 38—100% | |
| Loans to customers (net) | — | — | — | — | 122—1.0% | — | — | — | — | — | |
| Property, plant and equipment | 567−18.4%7.5% | 695−10.3%9.3% | 775−13.7%10.3% | 898−8.3%9.5% | 979−9.0%7.7% | 1,077+870%10.8% | 111−24.0%5.1% | 1460.0%5.2% | 146—88.6% | — | |
| Right-of-use (leased) assets | 72—1.0% | — | 31−50.0%0.4% | 63+230%0.7% | 19—0.1% | — | 9.6—0.4% | — | — | — | |
| Goodwill | 1,7200.0%22.8% | 1,720−65.8%23.0% | 5,0220.0%66.8% | 5,022−6.1%53.1% | 5,349−29.0%42.0% | 7,530+338%75.8% | 1,7190.0%78.2% | 1,719—61.2% | — | — | |
| Other intangible assets | 200−23.2%2.7% | 261−60.9%3.5% | 667−14.5%8.9% | 780−15.8%8.3% | 927−7.9%7.3% | 1,007r1,007+251%10.1% | 287r315−3.1%13.1% | 296r352—10.5% | — | — | |
| Non-current assets | — | — | — | — | — | — | 2,155—98.0% | — | — | — | |
| Total assets | 7,548+1.0%100% | 7,470−0.6%100% | 7,517−20.5%100% | 9,456−25.8%100% | 12,740+28.3%100% | 9,927+352%100% | 2,198−21.7%100% | 2,808+1603%100% | 165+337%100% | 38—100% | |
| Accounts payable | 503−28.1%6.7% | 699+2.7%9.4% | 680+27.2%9.0% | 535−16.4%5.7% | 640−32.0%5.0% | 941+21.9%9.5% | 772+165%35.1% | 292+2264%10.4% | 12+197%7.5% | 4.1—11.0% | |
| Customer deposits | — | — | — | 2500.0%2.6% | 250—2.0% | — | — | — | — | — | |
| Debt due within a year | — | — | 2,000—26.6% | — | — | — | — | 0−100%0.0% | 1.8r1.80.0%1.1% | 1.8r1.6—4.8% | |
| Current liabilities | 784−20.2%10.4% | 983−1.6%13.2% | 999+33.5%13.3% | 749−3.9%7.9% | 779−69.7%6.1% | 2,569+27.0%25.9% | 2,022+402%92.0% | 403+829%14.4% | 43+197%26.3% | 15—38.7% | |
| Lease liabilities (non-current) | 48—0.6% | — | — | 34—0.4% | — | — | — | — | — | — | |
| Total liabilities | 868−16.6%11.5% | 1,041−3.5%13.9% | 1,079+22.1%14.4% | 883+0.3%9.3% | 880−68.7%6.9% | 2,815+39.2%28.4% | 2,022—92.0% | — | — | 15—38.7% | |
| Retained earnings | −46,692—−619% | −38,463—−515% | −27,980—−372% | −22,495—−238% | −18,011—−141% | −11,835—−119% | −8,902—−405% | −6,181—−220% | −2,849—−1728% | −177—−470% | |
| Shareholders' equity | 6,679+3.9%88.5% | 6,429−0.1%86.1% | 6,438−24.9%85.6% | 8,573−27.7%90.7% | 11,859+66.8%93.1% | 7,112+3954%71.6% | 175−92.7%8.0% | 2,405+1879%85.6% | 122+426%73.7% | 23—61.3% | |
| Total liabilities and equity | 7,548+1.0%100% | 7,470−0.6%100% | 7,517−20.5%100% | 9,456−25.8%100% | 12,740+28.3%100% | 9,927+352%100% | 2,198−21.7%100% | 2,808+1603%100% | 165+337%100% | 38—100% | |
| Shares outstanding | 12r12+9.8%— | 11r11+25.0%— | 8.9r8.9+13.1%— | 7.8−14.4%— | 9.2r7.8+46.3%— | 6.3r6.3+15.0%— | 5.4+0.3%— | 5.4r22−74.0%— | 21+34.1%— | 16—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 194−32.0%9.5% | 285−0.9%13.3% | 288−12.8%13.8% | 330+6.9%15.9% | 309+92.8%21.7% | 160+122%17.0% | 72+95.0%19.5% | 37—15.1% | — | — | |
| Share-based compensation | 2,634+86.9%129% | 1,409+182%65.9% | 500−31.7%24.0% | 732+101%35.2% | 365−81.8%25.7% | 2,005+693%212% | 253−85.7%68.2% | 1,764—719% | — | 7.8—— | |
| Cash from operating activities | −5,135—−252% | −4,627—−216% | −3,528—−169% | −2,987—−144% | −2,809—−198% | −297—−31.5% | −894—−241% | −1,105—−451% | −93—— | −148—— | |
| Capital expenditure | −5.3—−0.3% | −92—−4.3% | −52—−2.5% | −79—−3.8% | −82—−5.7% | — | — | −4.2—−1.7% | — | — | |
| Cash from investing activities | −5.3—−0.3% | −92—−4.3% | −52—−2.5% | −79—−3.8% | −82−222%−5.7% | 67—7.1% | — | −404—−165% | — | — | |
| Debt issued | — | — | 107—5.1% | — | — | — | 250—67.4% | — | — | — | |
| Debt repaid | — | — | — | — | — | −339—−35.9% | — | — | — | — | |
| Shares issued | 5,306−36.9%261% | 8,407r2,554—393% | — | — | 583+13.2%41.0% | 515—54.6% | — | 1,500+2900%612% | 50−71.4%— | 175—— | |
| Cash from financing activities | 5,403−36.7%265% | 8,537+309%399% | 2,087+1204%100% | 160−97.9%7.7% | 7,631+1952%537% | 372−13.6%39.4% | 430−78.3%116% | 1,984+2917%809% | 66−62.4%— | 175—— | |
| Exchange-rate effect on cash | — | — | — | — | — | — | −0.3−164%−0.1% | 0.4—0.2% | −0.0−160%— | 0.0—— | |
| Change in cash | — | — | — | — | 4,740+3242%333% | 142—15.0% | −464−198%−125% | 475—194% | −27−200%— | 27—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jul 31, 2026 | Q2 FY2026to Jul 31, 2026 | Q1 FY2026to Apr 30, 2026 | Q4 FY2025to Jan 31, 2026 | Q3 FY2025to Oct 31, 2025 | Q2 FY2025to Jul 31, 2025 | Q1 FY2025to Apr 30, 2025 | Q4 FY2024to Jan 31, 2025 | Q3 FY2024to Oct 31, 2024 | Q2 FY2024to Jul 31, 2024 | Q1 FY2024to Apr 30, 2024 | Q4 FY2023to Jan 31, 2024 | Q3 FY2023to Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 1,618−37.3%100% | 438−29.7%100% | 433−35.1%100% | 401*−37.6%100% | 346−46.4%100% | 622+40.6%100% | 667+63.4%100% | 642*+22.4%100% | 646+50.9%100% | 443—100% | 409—100% | 525*—100% | 428—100% | |
| Cost of revenue | 1,082−36.1%66.9% | 256−45.1%58.4% | 237−43.1%54.6% | 312*−12.5%77.8% | 278−39.0%80.2% | 466+36.4%74.8% | 415+70.4%62.2% | 356*+3.8%55.5% | 455+69.1%70.4% | 341—77.1% | 244—59.7% | 343*—65.5% | 269—62.9% | |
| Gross profit | — | — | — | 89*−68.9%22.2% | 69−64.1%19.8% | 157+54.5%25.2% | 252+52.9%37.8% | 286*+57.8%44.5% | 191+19.6%29.6% | 102—22.9% | 165—40.3% | 181*—34.5% | 160—37.3% | |
| Research and development | 1,215−53.6%75.1% | 322−42.7%73.6% | 247−63.8%57.1% | 188*−61.6%46.9% | 457−48.1%132% | 563−27.3%90.4% | 683−29.9%102% | 490*−13.0%76.3% | 881+59.7%136% | 774—175% | 975—239% | 563*—107% | 552—129% | |
| Selling, general and administrative | 6,368+25.4%394% | 750−53.0%171% | 1,204+22.6%278% | 922*−47.6%230% | 3,492+374%1009% | 1,598+117%257% | 982−9.0%147% | 1,760*+90.4%274% | 737−44.6%114% | 737—167% | 1,080—264% | 924*—176% | 1,331—311% | |
| Operating expenses | — | — | — | 1,110*−81.0%277% | 3,949+144%1141% | 2,160+42.9%347% | 1,665−18.9%250% | 5,845*+299%910% | 1,618−15.2%251% | 1,511—341% | 2,054—503% | 1,464*—279% | 1,907—446% | |
| Total costs and expenses | 8,664−33.3%536% | 1,328−49.4%304% | 1,688−18.9%389% | 1,422*−77.1%355% | 4,226+104%1221% | 2,626+41.7%422% | 2,081−9.4%312% | 6,201*+239%965% | 2,073−3.7%321% | 1,853—418% | 2,298—563% | 1,831*—349% | 2,151—503% | |
| Operating income | −7,046—−436% | −891—−204% | −1,254—−289% | −1,021*—−255% | −3,880—−1121% | −2,003—−322% | −1,413—−212% | −5,559*—−865% | −1,427—−221% | −1,410—−318% | −1,889—−463% | −1,306*—−249% | −1,724—−403% | |
| Interest and finance income | — | 15+72.9%3.4% | — | 58*+26.3%14.5% | 14−80.2%3.9% | 8.6−88.8%1.4% | 31+169389%4.6% | 46*+1426%7.2% | 68+1712%10.6% | 77—17.5% | 0.0—0.0% | 3.0*—0.6% | 3.8—0.9% | |
| Interest expense and finance costs | 21+29.0%1.3% | 4.9−15.6%1.1% | 5.0+96.5%1.2% | 5.3*+42.7%1.3% | 5.5+37.6%1.6% | 5.8+15.0%0.9% | 2.5−1.1%0.4% | 3.7*−83.9%0.6% | 4.0−90.0%0.6% | 5.0—1.1% | 2.6r8.6—0.6% | 23*—4.4% | 40r40—9.4% | |
| Other non-operating income (expense) | 83−37.9%5.1% | 10+250%2.3% | 12−49.7%2.9% | 53*+24.8%13.2% | 8.0−87.6%2.3% | 2.9—0.5% | 25—3.7% | 42*—6.6% | 64—9.9% | −296—−66.8% | −8.6—−2.1% | −575*—−110% | −36—−8.5% | |
| Income before tax | −6,963—−430% | −881—−201% | −1,242—−287% | −968*—−242% | −3,872—−1119% | −2,000—−321% | −1,389—−208% | −5,516*—−859% | −1,363—−211% | −1,705—−385% | −1,898—−465% | −1,881*—−359% | −1,760—−411% | |
| Net income attributable to shareholders | −6,963—−430% | −881—−201% | −1,242—−287% | −968*—−242% | −3,872—−1119% | −2,000—−321% | −1,389—−208% | −5,516*—−859% | −1,363—−211% | −1,705—−385% | −1,898—−465% | −1,881*—−359% | −1,760—−411% | |
| Earnings per share, basic | — | -0.07—— | -0.10—— | — | -0.32—— | -2.12—— | -0.12—— | — | -0.12—— | -0.15—— | -0.21—— | — | -0.22—— | |
| Earnings per share, diluted | — | -0.07—— | -0.10—— | — | -0.32—— | -2.12—— | -0.12—— | — | -0.12—— | -0.15—— | -0.21—— | — | -0.22—— | |
| Shares, weighted average (basic) | 12+8.4%— | 12+8.4%— | 12+9.3%— | — | 12+8.6%— | 11+1.4%— | 11+21.5%— | — | 11+41.7%— | 11—— | 9.2—— | — | 7.8—— | |
| Shares, weighted average (diluted) | 12+8.4%— | 12+8.4%— | 12+9.3%— | — | 12+8.6%— | 11+1.4%— | 11+21.5%— | — | 11+41.7%— | 11—— | 9.2—— | — | 7.8—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 3,422—54.4% | 3,422−51.1%54.4% | 4,006+35.2%58.1% | 4,575+6.1%60.6% | 5,312−6.8%63.1% | 6,995+3.5%68.7% | 2,964−64.5%48.2% | 4,312+775%57.7% | 5,698+350%45.4% | 6,760—49.6% | 8,348—55.1% | 493—6.6% | 1,265—14.8% | |
| Receivables | 24—0.4% | 24−85.3%0.4% | 2.6−97.2%0.0% | 118+60.3%1.6% | 148+34.6%1.8% | 161+136%1.6% | 94+10.6%1.5% | 74−50.3%1.0% | 110−35.4%0.9% | 68—0.5% | 85—0.6% | 149—2.0% | 170—2.0% | |
| Inventory | 171—2.7% | 171+23.7%2.7% | 121−43.6%1.8% | 118−44.4%1.6% | 136−19.2%1.6% | 138−38.3%1.4% | 215+27.8%3.5% | 212+25.8%2.8% | 168−3.6%1.3% | 224—1.6% | 169—1.1% | 169—2.2% | 175—2.0% | |
| Current assets | 3,819—60.7% | 3,819−49.2%60.7% | 4,376+27.6%63.5% | 4,989+4.1%66.1% | 5,815−6.1%69.1% | 7,520+3.8%73.9% | 3,430−60.7%55.7% | 4,794+369%64.2% | 6,192+210%49.4% | 7,248—53.2% | 8,730—57.6% | 1,022—13.6% | 2,000—23.5% | |
| Property, plant and equipment | 530—8.4% | 530−13.9%8.4% | 548−16.7%8.0% | 567−18.4%7.5% | 588−20.5%7.0% | 616−16.5%6.1% | 658−11.1%10.7% | 695−10.3%9.3% | 740−3.5%5.9% | 738—5.4% | 740—4.9% | 775—10.3% | 767—9.0% | |
| Right-of-use (leased) assets | 54—0.9% | 54−40.0%0.9% | 63−36.4%0.9% | 72—1.0% | 81+933%1.0% | 90+474%0.9% | 99+321%1.6% | — | 7.8−80.0%0.1% | 16—0.1% | 24—0.2% | 31—0.4% | 39—0.5% | |
| Goodwill | 1,720—27.3% | 1,7200.0%27.3% | 1,7200.0%24.9% | 1,7200.0%22.8% | 1,720−65.8%20.4% | 1,720−65.8%16.9% | 1,720−65.8%28.0% | 1,720−65.8%23.0% | 5,0220.0%40.0% | 5,022—36.8% | 5,022—33.1% | 5,022—66.8% | 5,022—58.9% | |
| Other intangible assets | 170—2.7% | 170−26.3%2.7% | 185−24.7%2.7% | 200−23.2%2.7% | 216−63.0%2.6% | 231−62.2%2.3% | 246−61.5%4.0% | 261−60.9%3.5% | 582−16.3%4.6% | 611—4.5% | 639—4.2% | 667—8.9% | 696—8.2% | |
| Total assets | 6,293—100% | 6,293−38.2%100% | 6,892+12.0%100% | 7,548+1.0%100% | 8,419−32.9%100% | 10,177−25.4%100% | 6,152−59.4%100% | 7,470−0.6%100% | 12,543+47.2%100% | 13,634—100% | 15,154—100% | 7,517—100% | 8,523—100% | |
| Accounts payable | 645—10.2% | 645−53.7%10.2% | 639−11.4%9.3% | 503−28.1%6.7% | 605−32.2%7.2% | 1,393+78.9%13.7% | 722−27.4%11.7% | 699+2.7%9.4% | 892+130%7.1% | 779—5.7% | 994—6.6% | 680—9.0% | 388—4.6% | |
| Customer deposits | — | — | — | — | — | — | — | — | — | — | — | — | 250—2.9% | |
| Debt due within a year | — | — | — | — | — | — | — | — | — | — | — | 2,000—26.6% | — | |
| Current liabilities | 907—14.4% | 907−42.3%14.4% | 832−10.0%12.1% | 784−20.2%10.4% | 773−38.1%9.2% | 1,572+42.4%15.4% | 925−34.7%15.0% | 983−1.6%13.2% | 1,248+73.8%9.9% | 1,104—8.1% | 1,417—9.3% | 999—13.3% | 718—8.4% | |
| Lease liabilities (non-current) | 32—0.5% | 32−49.4%0.5% | 40−43.3%0.6% | 48—0.6% | 56—0.7% | 64—0.6% | 71—1.2% | — | — | — | — | — | 8.9—0.1% | |
| Total liabilities | 964—15.3% | 964−42.7%15.3% | 902−14.0%13.1% | 868−16.6%11.5% | 870−33.6%10.3% | 1,683+43.5%16.5% | 1,049−41.5%17.0% | 1,041−3.5%13.9% | 1,312−53.4%10.5% | 1,173—8.6% | 1,791—11.8% | 1,079—14.4% | 2,812—33.0% | |
| Retained earnings | −48,815—−776% | −48,815—−776% | −47,934—−695% | −46,692—−619% | −45,724—−543% | −41,852—−411% | −39,852—−648% | −38,463—−515% | −32,946—−263% | −31,584—−232% | −29,878—−197% | −27,980—−372% | −26,099—−306% | |
| Shareholders' equity | 5,329—84.7% | 5,329−37.3%84.7% | 5,990+17.4%86.9% | 6,679+3.9%88.5% | 7,549−32.8%89.7% | 8,494−31.8%83.5% | 5,103−61.8%83.0% | 6,429−0.1%86.1% | 11,232+96.7%89.5% | 12,461—91.4% | 13,363—88.2% | 6,438—85.6% | 5,711—67.0% | |
| Total liabilities and equity | 6,293—100% | 6,293−38.2%100% | 6,892+12.0%100% | 7,548+1.0%100% | 8,419−32.9%100% | 10,177−25.4%100% | 6,152−59.4%100% | 7,470−0.6%100% | 12,543+47.2%100% | 13,634—100% | 15,154—100% | 7,517—100% | 8,523—100% | |
| Shares outstanding | 12—— | 12+1.2%— | 12+9.2%— | 12r12+9.8%— | 12+9.6%— | 12+8.3%— | 11+1.5%— | 11r11+25.0%— | 11+41.8%— | 11—— | 11—— | 8.9r8.9—— | 7.8—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 146−43.9%9.0% | 33*−41.9%7.6% | 34−40.5%7.9% | 36*−50.8%9.0% | 43−41.3%12.4% | 57−18.0%9.2% | 57−16.8%8.6% | 73*+5.1%11.3% | 73+8.7%11.3% | 70—15.8% | 69—16.9% | 69*—13.2% | 67—15.7% | |
| Share-based compensation | — | — | 552—127% | 99*−88.5%24.6% | — | — | — | 856*—133% | 0*−100%0.0% | 130*—29.4% | 423—104% | 0*—0.0% | 425r338*—99.3% | |
| Cash from operating activities | −3,632—−225% | −585*—−134% | −563—−130% | −732*—−183% | −1,752*—−506% | −1,313*—−211% | −1,337—−200% | −1,239*—−193% | −1,010*—−156% | −1,544*—−349% | −834—−204% | −718*—−137% | −1,064*—−249% | |
| Capital expenditure | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | −5.3—−0.8% | 0*—0.0% | −47*—−7.3% | −39*—−8.8% | −6.2—−1.5% | −49*—−9.4% | 0*—0.0% | |
| Cash from investing activities | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | −5.3—−0.8% | 0*—0.0% | −47*—−7.3% | −39*—−8.8% | −6.2—−1.5% | −49*—−9.4% | 0*—0.0% | |
| Debt issued | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | |
| Shares issued | — | — | — | 0*−100%0.0% | 0*—0.0% | — | — | 6.6r−5,846*—1.0% | 0*—0.0% | — | — | — | — | |
| Cash from financing activities | 59−98.9%3.6% | 0.4*−100.0%0.1% | −5.6—−1.3% | −5.5*—−1.4% | 70*—20.1% | 5,344r5,344*—859% | −5.3r−5.3−100%−0.8% | −147*—−22.9% | −5.2*—−0.8% | −5.1*—−1.2% | 8,695—2128% | −5.0*—−1.0% | −5.0*—−1.2% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jul 31, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Nutriband Inc. sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Sale of Goods$2 M100%-4.7%
Business segments
- Pocono Pharmaceuticals$2 M100%-4.7%
Countries and regions
- 🇺🇸 USA$2 M100%-5.1%
- Foreign(total)$0 M0.4%—
Source: SEC annual report (XBRL data) · as of Jan 31, 2026
Events at Nutriband Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 1 · Material agreement 2 · Unregistered share sale 4 · Bylaws or fiscal year changed 2 · Shareholder vote 3
| Filed | What happened | Filing |
|---|---|---|
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Unregistered share saleBylaws or fiscal year changed | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Unregistered share sale | 8-K/A | |
| Unregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Unregistered share sale | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jun 22, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2018 | $1 M | No. 1 | Under $2 million | 1 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Nutriband Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $58 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Internal Control SpecialistEconomists | 1 | $58 K |
Where: Orlando, FL 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Nutriband, Inc.
How Nutriband Inc. compares in Biotechnology
- Market cap$79 M · higher than 33% of 726
- Revenue$2 M · higher than 30% of 647
- Net margin-429.6% · higher than 15% of 408
- Revenue growth-4.7% · higher than 39% of 438
- Price / sales48.7× · lower than 18% of 339
- Price / book11.8× · lower than 13% of 534
- FCF yield-6.5% · higher than 66% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Nutriband Inc.🇺🇸 | $79 M | — | -429.6% | -4.7% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending January-2026
- Balance sheet:
- As of January-2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Nutriband Inc.? Verify and update this profile — free
Show Nutriband Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.